Abstract
Integration of the omics data, including metabolomics and proteomics, provides a unique opportunity to search for new associations in the context of metabolic disorders, including Alzheimer’ s disease. Using targeted metabolomics, we have previously profiled lipid mediators, including oxylipins, endocannabinoids, bile acids and steroids in 293 CSF and 202 matched plasma samples from AD cases and healthy controls, and identified both central and peripheral metabolites of the inflammation-regulating cytochrome p450/soluble epoxide hydrolase pathway as strong predictors for the AD pathology. Additionally, using proteomics, we have identified five cerebrospinal fluid protein panels, involved in regulation of energy metabolism, vasculature, myelin/oligodendrocyte, glia/inflammation, and synapses/neurons affected in AD, and reflective of AD-related changes in brain. In the current manuscript, using metabolomics-proteomics data integration, we describe new associations between peripheral and central lipid mediators, with the above-described cerebrospinal fluid protein panels. Particularly strong associations were observed between cytochrome p450/soluble epoxide hydrolase metabolites, bile acids and CSF proteins involved in glycolysis, blood coagulation and vascular inflammation and the regulators of extracellular matrix. Those metabolic associations were not observed at the gene-coexpression level in the central nervous system, showing the importance of pathway interaction investigation on the level of the terminal part of the biochemical “ omic” cascade. In summary, this manuscript provides new information regarding the Alzheimer’ s disease, linking both central and peripheral inflammatory cascade of cytochrome p450/soluble epoxide hydrolase and bile acids metabolism with AD-affected processes and illustrates the necessity for the “ omics” data integration to uncover associations beyond gene co-expression.
Competing Interest Statement
Dr. Kaddurah-Daouk in an inventor on a series of patents on use of metabolomics for the diagnosis and treatment of CNS diseases and holds equity in Metabolon Inc., Chymia LLC and PsyProtix, which were not involved in this study. Matthias Arnold is co-inventor (through Duke University/Helmholtz Zentrum Munchen) on patents on applications of metabolomics in diseases of the central nervous system. Matthias Arnold also holds equity in Chymia LLC and IP in PsyProtix and Atai that is unrelated to this work. Kamil Borkowski (through Duke University/UC Davis) is a coinventor on a patent of targeting lipid mediators in Alzheimer's disease. All other authors declare that they have no competing interests.
Funding Statement
The Alzheimer's Disease Metabolomics Consortium (ADMC) is funded wholly or in part by the following National Institute on Aging (NIA) grants and supplements, components of the Accelerating Medicines Partnership for AD (AMP-AD) and/or Molecular Mechanisms of the Vascular Etiology of AD (M2OVE-AD): NIA R01AG046171, RF1AG051550, RF1AG057452, R01AG059093, RF1AG058942, U01AG061359, U19AG063744 and FNIH: #DAOU16AMPA awarded to Dr. Kaddurah-Daouk at Duke University in partnership with a large number of academic institutions. Matthias Arnold is further supported by the NIA through grant R01AG069901. Additional support was provided by Emory ADRC P30 AG066511 awarded to Allan I. Levey, Emory EHBS R01 AG070937 awarded to James J. Lah and USDA Intramural Projects 2032-51530-022-00D and 2032-51530-025-00D awarded to John W. Newman. The USDA is an equal opportunity employer and provider.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All participants from whom plasma and CSF samples were collected provided informed consent under protocols approved by the Institutional Review Board at Emory University. All protocols were reviewed and approved by the Emory University Institutional Review Board. Cohorts included the Emory Healthy Brain Study (IRB00080300), Cognitive Neurology Research (IRB00078273), and Memory @ Emory (IRB00079069).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Metabolomics data is provided by the Alzheimer's Disease Metabolomics Consortium (ADMC). Metabolomics data and pre-processed data are accessible through the Accelerating Medicines Partnership for AD (AMP-AD) Knowledge Portal (https://adknowledgeportal.synapse.org/). The AMP-AD Knowledge Portal is the distribution site for data, analysis results, analytical methodology and research tools generated by the AMP-AD Target Discovery and Preclinical Validation Consortium and multiple Consortia and research programs supported by the National Institute on Aging. Proteomic data and additional information on their generation is available from synapse.org at https://www.synapse.org/#!Synapse:syn20821165/wiki/603119.
